Iterum Therapeutics PLC (NASDAQ:ITRM) Sees Significant Increase in Short Interest

Iterum Therapeutics PLC (NASDAQ:ITRM) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 3,065,983 shares, an increase of 49.9% from the February 26th total of 2,045,972 shares. Based on an average trading volume of 2,768,177 shares, the short-interest ratio is currently 1.1 days. Currently, 5.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. OneDigital Investment Advisors LLC lifted its position in Iterum Therapeutics by 18.6% during the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after acquiring an additional 30,000 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Iterum Therapeutics in the third quarter valued at approximately $32,000. Jane Street Group LLC bought a new position in shares of Iterum Therapeutics during the second quarter worth approximately $92,000. Alchemi Wealth LLC bought a new position in shares of Iterum Therapeutics during the fourth quarter worth approximately $90,000. Finally, Apollon Financial LLC lifted its holdings in Iterum Therapeutics by 151.8% during the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after purchasing an additional 380,000 shares during the last quarter. Institutional investors and hedge funds own 9.21% of the company’s stock.

Iterum Therapeutics Price Performance

NASDAQ:ITRM opened at $0.04 on Monday. The company has a market cap of $1.90 million, a P/E ratio of -0.05 and a beta of 2.96. The firm’s fifty day moving average price is $0.24 and its two-hundred day moving average price is $0.43. Iterum Therapeutics has a one year low of $0.03 and a one year high of $1.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ITRM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. Maxim Group cut Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 4th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.00.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).